Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.

Cancer Med · 2019 · PMC6718602 · PMID 31297962

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In KEYNOTE‐024, pembrolizumab also showed benefit in terms of PFSR6m (RR = 0.82, 95% CI: 0.68‐1.00, P = 0.047) and a trend toward significance in OSR6m (RR = 0.90, 95% CI: 0.79‐1.02, P = 0.089) compared with chemotherapy, by contrast, in KEYNOTE‐042, pembrolizumab showed a trend to increased early mortality (RR for OSR6m = 1.07, 95% CI: 0.99‐1.16).

also in 53,322 other papers

a trend toward significanceno p-value reported

While nivolumab combined with ipilimumab showed benefit in terms of mPFS (HR = 0.58, 95% CI: 0.41‐0.81), PFSR1y (RR = 0.30, 95% CI: 0.20‐0.47) and ORR (RR = 0.59, 95% CI: 0.43‐0.81) (all P < 0.05), and a trend toward significance of PFSR6m (RR = 0.82, 95% CI: 0.66‐1.01) compared with chemotherapy (Figure 3 ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.